# Cognitive Safety in Older Adults Cannabis Research Update > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cognitive-safety-older-adults-cannabis-march-2026/ > **Published:** 2026-03-07T13:59:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:00:15-04:00 > **Clinical Summary:** Explore the latest research on cognitive safety in older adults cannabis use alongside cannabinoids and fatty liver disease studies in March 2026. --- Last 24 Hours March 07, 2026 — 52 articles reviewed This cycle was dominated by widespread coverage of preclinical research showing cannabinoids may combat [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/), alongside a cluster of state-level policy developments affecting patient access from Alabama to West Virginia. Significant clinical evidence also emerged on cognitive safety in older adults, [anxiety relief](https://cedclinic.com/cannabis-based-medicine-ptsd-anxiety-relief/) from CBD-dominant products, and cannabis extracts for myofascial pain. Jump to section[Cannabinoids and Fatty Liver Disease: One Study, Massive Coverage](#cannabinoids-and-fatty-liver-disease-one)[Cognitive Safety and Anxiety Relief: Reassuring Data for Older Adults](#cognitive-safety-and-anxiety-relief-reas)[Myofascial Pain and Drug Delivery: Clinical Tools Getting Sharper](#myofascial-pain-and-drug-delivery-clinic)[?️ State Policy Movement: Access Expanding but Infrastructure Lagging](#state-policy-movement-access-expanding-b)[Occupational Access and Public Safety: Firefighters Still Waiting](#occupational-access-and-public-safety-fi)[⚠️ Regulatory Gaps: Unregulated Products, Drug Testing, and Youth Access](#regulatory-gaps-unregulated-products-dru) The liver disease research is genuinely exciting, the cognitive safety data is genuinely reassuring, and the policy landscape is genuinely messy. Our job as clinicians has not changed: follow the evidence, protect the patient, and insist that legal access comes with clinical infrastructure worthy of the people we serve. Browse all recent articles at [cedclinic.com/category/cannabis-news/](https://cedclinic.com/category/cannabis-news/) Digest-Level Clinical Commentary Dr. Caplan’s Take Clinical Reflection The convergence of preclinical hepatic data with clinical cognitive safety findings in older adults suggests we’re moving toward a more nuanced risk-benefit framework in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), particularly for polypharmacy populations where drug interactions and liver metabolism are clinical concerns. While the [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) research remains preliminary, the emerging cognitive safety data in our aging demographic is clinically relevant since this population represents a growing proportion of my [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) consultations. These developments point toward a practice evolution where we can offer more evidence-informed counseling about both potential metabolic benefits and safety profiles, though we’ll need robust prospective trials before recommending cannabis specifically for NAFLD. Clinical Perspective Clinical Perspective Recent preclinical findings on cannabinoids and fatty liver disease, coupled with emerging clinical data on cognitive safety in older populations, suggest a measured expansion of the evidence base beyond traditional indications. The convergence of [anxiety relief](https://cedclinic.com/cannabis-based-medicine-ptsd-anxiety-relief/) data with safety signals in vulnerable populations indicates that future clinical applications will likely depend on more rigorous stratification by age, liver function, and cognitive status. These developments reflect a shift toward evidence-based risk-benefit assessment rather than broad therapeutic claims. ResearchCannabinoids[Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/)Health BenefitsRegulatory News 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Daily+Digest%3A+Last+24+Hours%3A+Cannabinoids+and+Liver+Disease+Lead+a+Busy+News+Cycle+%E2%80%94+March+07%2C+2026+%40drcaplan&url=) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Daily+Digest%3A+Last+24+Hours%3A+Cannabinoids+and+Liver+Disease+Lead+a+Busy+News+Cycle+%E2%80%94+March+07%2C+2026+--+via+%40drcaplan.bsky.social+) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Daily Digest: Last 38 Hours: Cannabinoids, Liver Disease, and the Adolescent Brain — March 08, 2026](https://cedclinic.com/cannabinoid-drug-delivery-breakthroughs-march-2026/) - [In the Mix: 20 More Articles — March 08, 2026](https://cedclinic.com/cannabis-pediatric-exposure-toxicity-march-08-2026/) - [Daily Digest: Last 24 Hours: Cannabinoids and Liver Disease Lead a Research-Heavy Cycle — March 08, 2026](https://cedclinic.com/cbd-cbg-fatty-liver-disease-research-march-2026/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Discover how recent studies highlight the potential of [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) in combating fatty liver disease. [Read More](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) [Daily Digest: Last 9 Hours: Cognitive Safety Data, End-of-Life Access, and Regulatory Friction — March 05, 2026](https://cedclinic.com/cognitive-safety-in-older-adults-cannabis-march-2026/) Review the latest clinical evidence on cognitive safety of cannabis use in older adults and related regulatory updates. [Explore Insights](https://cedclinic.com/cognitive-safety-in-older-adults-cannabis-march-2026/) [New Research Shows Cannabis Compounds May Boost Liver and Heart Health – Muscle & Fitness](https://cedclinic.com/cannabinoids-hepatoprotective-properties-liver-heart-health/) Learn about new findings on how [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) may support liver and heart health from recent research. [Learn More](https://cedclinic.com/cannabinoids-hepatoprotective-properties-liver-heart-health/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).